Elmer Maurits
Overview
Explore the profile of Elmer Maurits including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
214
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Su Q, Louwerse M, Lammers R, Maurits E, Janssen M, Boot R, et al.
Chem Sci
. 2024 Sep;
PMID: 39246358
GBA2, the non-lysosomal β-glucosylceramidase, is an enzyme involved in glucosylceramide metabolism. Pharmacological inhibition of GBA2 by -alkyl iminosugars is well tolerated and benefits patients suffering from Sandhoff and Niemann-Pick type...
2.
Inholz K, Anderl J, Klawitter M, Goebel H, Maurits E, Kirk C, et al.
Eur J Immunol
. 2024 Mar;
54(4):e2350613.
PMID: 38458995
Immunoproteasomes are a special class of proteasomes, which can be induced with IFN-γ in an inflammatory environment. In recent years, it became evident that certain immune cell types constitutively express...
3.
Zhou X, Besse A, Peter J, Steinhardt M, Vogt C, Nerreter S, et al.
Haematologica
. 2023 Feb;
108(6):1628-1639.
PMID: 36727403
Optimal carfilzomib dosing is a matter of debate. We analyzed the inhibition profiles of proteolytic proteasome subunits β5, β2 and β1 after low-dose (20/27 mg/m2) versus high-dose (≥36 mg/m2) carfilzomib...
4.
Besse A, Kraus M, Mendez-Lopez M, Maurits E, Overkleeft H, Driessen C, et al.
Cells
. 2022 Mar;
11(5).
PMID: 35269460
Targeting proteasome with proteasome inhibitors (PIs) is an approved treatment strategy in multiple myeloma that has also been explored pre-clinically and clinically in other hematological malignancies. The approved PIs target...
5.
Besse L, Besse A, Kraus M, Maurits E, Overkleeft H, Bornhauser B, et al.
Cells
. 2021 Nov;
10(11).
PMID: 34831075
Proteasome inhibitors (PIs) are approved backbone treatments in multiple myeloma. More recently, inhibition of proteasome activity with the PI bortezomib has been clinically evaluated as a novel treatment strategy in...
6.
de Geus M, Groenewold G, Maurits E, Araman C, van Kasteren S
Chem Sci
. 2021 Jun;
11(37):10175-10179.
PMID: 34094281
The inverse electron-demand Diels-Alder (IEDDA) pyridazine elimination is one of the key bioorthogonal bond-breaking reactions. In this reaction -cyclooctene (TCO) serves as a tetrazine responsive caging moiety for amines, carboxylic...
7.
Maurits E, Degeling C, Kisselev A, Florea B, Overkleeft H
Chembiochem
. 2020 Jun;
21(22):3220-3224.
PMID: 32598532
Proteasomes are established therapeutic targets for hematological cancers and promising targets for autoimmune diseases. In the past, we have designed and synthesized mechanism-based proteasome inhibitors that are selective for the...
8.
Maurits E, van de Graaff M, Maiorana S, Wander D, Dekker P, van der Zanden S, et al.
J Am Chem Soc
. 2020 Apr;
142(16):7250-7253.
PMID: 32275401
Proteasome inhibitors are established therapeutic agents for the treatment of hematological cancers, as are anthracyclines such as doxorubicin. We here present a new drug targeting approach that combines both drug...
9.
de Geus M, Maurits E, Sarris A, Hansen T, Kloet M, Kamphorst K, et al.
Chemistry
. 2020 Mar;
26(44):9900-9904.
PMID: 32154603
The inverse electron demand Diels-Alder pyridazine elimination reaction between tetrazines and allylic substituted trans-cyclooctenes (TCOs) is a key player in bioorthogonal bond cleavage reactions. Determining the rate of elimination of...
10.
Xin B, Huber E, de Bruin G, Heinemeyer W, Maurits E, Espinal C, et al.
J Med Chem
. 2019 Jan;
62(3):1626-1642.
PMID: 30657666
Subunit-selective proteasome inhibitors are valuable tools to assess the biological and medicinal relevance of individual proteasome active sites. Whereas the inhibitors for the β1c, β1i, β5c, and β5i subunits exploit...